Ben Jenkins
@B_J_Jenkins
Followers
116
Following
135
Media
2
Statuses
43
Imiwnolegydd Cymraeg 🏴 • Post Doc in @NickJonesImmuno group @ Swansea University • Interested in immunometabolism and disease
Cwmllynfell / Swansea Uni
Joined October 2018
Delighted to be able to share our latest work, out today in @Cell_Metabolism. Here we show that canagliflozin - a type 2 diabetes drug - inhibits T cell function, which is underpinned by impaired metabolic rewiring. https://t.co/EHYjXXATlT
@Nickjonesimmuno @SwanseaUni
cell.com
Jenkins et al. report that the SGLT2 inhibitor, canagliflozin, compromises human T cell effector function. Canagliflozin prevents T cell activation and proliferation by antagonizing TCR signaling,...
4
7
40
Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function @NatureComms @B_J_Jenkins @Nickjonesimmuno @EmmaEVincent @SwanseaUni 🇬🇧 https://t.co/B8AwRJknTE
0
4
24
Ecstatic to share out latest research looking at the role of mitochondrial ABHD11 in controlling T-cell responses. We think this may be a viable target for autoimmunity. Please do give it a read, we would love to hear your thoughts. https://t.co/pO4S6x4fFw
nature.com
Nature Communications - α/β-hydrolase domain-containing protein 11 (ABHD11) is a mitochondrial hydrolase, and its expression in CD4 + T-cells has been linked to remission...
1
1
4
Secondly, PhD student Emma Lucas and myself contributed towards how metabolism shapes relapsed/refractory T-cell acute lymphoblastic leukaemia, led by João Barata and colleagues from the T-ALL special interest group https://t.co/KTl9X0wpZy
nature.com
Leukemia - Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia
0
1
2
The first takes a look at repurposing metabolic drugs as anti-inflammatory agents with @B_J_Jenkins and @OSheaHoganLab
https://t.co/1BF8tWZy0R
cell.com
Dysregulation of bodyweight systemic metabolism is intrinsically linked to an inflammatory phenotype, with each underpinning the other. Over the past decade, new classes of drug, such as glucagon-l...
1
1
2
Really pleased to share two review articles the lab has been involved in lately 👇🏻 Thanks for the involvement!
1
1
2
🧪Postdoc job alert! #Immunometabolism We are recruiting a postdoc to work on human immunometabolism at Swansea University! Come and work in a fully outfitted, vibrant research lab by the beach 🏖️ Details and application: https://t.co/6Rpq43NV6C Deadline: 29th February 2024!
1
14
16
Awesome to see our work being featured on the cover of this month's issue of @Cell_Metabolism! Massive thanks again to everyone who's helped with this project
Our July #NewIssue is out! Ft. cover art by 1st author Benjamin J Jenkins depicting the immunometabolic underpinnings of autoimmune conditions such as rheumatoid arthritis Read the #openaccess paper: Canagliflozin impairs T cell effector function via metabolic suppression in
2
1
26
‘Autoimmunity, Inflammation and Immune Privilege’ session: excellent talks from Lucy Walker, David Wraith, Ben Jenkins and Dave Copland. From ocular autoimmunity to 🎯 costimulation, immunometabolism, and antigen-specific cells in autoimmunity👌#BSIBristol23 #CMMBristol
0
3
9
Glycogen-fuelled metabolism supports rapid Mucosal Associated Invariant T cell responses https://t.co/XYtw2GRknH Cheers to @FearonCassidy and @AndyHogan82 on a fantastic study. As always loved being a part with @B_J_Jenkins 🎉🥂@SwanseaMedicine
pnas.org
Mucosal-associated invariant T (MAIT) cells are a subset of unconventional T cells which recognize a limited repertoire of ligands presented by the...
0
5
46
🚨Last weeks #immunometabolism discoveries @Bims_BiomedNews ⬇️⬇️⬇️ https://t.co/u4i1oL4bV9 Highlight: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, impairs T cell effector function AND more inside!
0
13
35
🔬Astudiaeth newydd: Mae ymchwilwyr @SwanseaMedicine wedi canfod y gall cyffur a ddefnyddir yn gyffredin i drin diabetes math 2 helpu i drin anhwylderau awtoimiwnedd o bosib. @Nickjonesimmuno @B_J_Jenkins @Cell_Metabolism ➡️ https://t.co/IeALM22Ae6
0
1
4
🔬New study: Researchers @Nickjonesimmuno @B_J_Jenkins @SwanseaMedicine have found that a drug commonly used to treat type 2 diabetes can potentially be used in the treatment of autoimmune disorders. @Cell_Metabolism ➡️ https://t.co/UgB6kuf0P1
1
6
19
Please see this tweetorial by @Nickjonesimmuno if you're interested in hearing a bit more about the how the work came together! https://t.co/e0rLf5i2TT
👋🏻 Excited to share my lab’s first (!) work today published in @Cell_Metabolism where we demonstrate that the type 2 diabetes drug, canagliflozin, impairs human T-cell effector function via metabolic suppression led by @B_J_Jenkins –
0
0
1
Thank you to everyone who has been involved in the project over the last couple of years, particularly @Nickjonesimmuno and the rest of the group @SwanseaUni @SwanseaMedicine
1
0
1
New! Online now: Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
cell.com
Jenkins et al. report that the SGLT2 inhibitor, canagliflozin, compromises human T cell effector function. Canagliflozin prevents T cell activation and proliferation by antagonizing TCR signaling,...
1
13
37
@QUBelfast @BelfastTrust Next is the BSI Immunology Teaching Excellence Award, which recognises an exceptional #immunology teacher working in higher education in the UK This year the award is shared by Dr @RutschmannS at @imperialcollege & Dr Tom Wilkinson at @SwanseaUni 👨🏫👏
2
3
21
Awesome few days at #BSI22 in Liverpool - thanks to everyone who took the time to come and have a chat about our work yesterday, really enjoyed all the discussion
1
2
36
Looking forward to #BSI22 - if you've got any interest in T cells, autoimmunity and/or immunometabolism, please come and have a look at our work at P-508 this week!
0
0
11